DIA 48th Annual Meeting
Click here to go to the previous page
Strategically Reduce Study Cost by Controlling Study Design Cost Drivers, with Attention to Studies with Biomarkers
Track : Track 02: Project/Portfolio Management and Strategic Planning
Program Code: 414
Date: Thursday, June 28, 2012
Time: 10:45 AM to 12:15 PM  EST
Michael Palmer, Adaptive Pharmacogenomics, LLC, United States
 William Sietsema, INC Research, Inc., United States
Michael Palmer, Adaptive Pharmacogenomics, LLC, United States
 Philip Dehazya, Aptiv Solutions, United States
Development planning, including modeling study cost, is critical to the success of any product. A rigorous methodology based on research done with the FDA and a large pharma exists for objectively and quantitatively modeling and understanding study cost, including studies with biomarkers. Guided by this modeling, the clinical development strategist can revise study strategy to save money while preserving objectives.

Learning Objectives:
Discuss how to capture study design uncertainty as base case, best case, and worst case
Explain how to assign cost to specific components of study design
Evaluate study design features and cost to understand how to maintain study objectives while potentially lowering the study cost.